Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Cardiac Contractility & Myocardial Performance: Therapeutic Implications of Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses

Author and Cardiovascular Three-volume Series, Editor: Justin Pearlman, MD, PhD, FACC

Author and Curator: Larry H Bernstein, MD, FCAP

http://pharmaceuticalintelligence.com/2013/08/28/cardiac-contractility-myocardium-performance-ventricular-arrhythmias-and-non-ischemic-heart-failure-therapeutic-implications-for-cardiomyocyte-ryanopathy-calcium-release-related-contractile/

Therapeutic Implications of Pharmacological Agents for Cardiac  Contractility Dysfunction: “The Fire From Within The Biggest Ca²⁺ Channel Erupts and Dribbles” by Anderson, ME

Author: Justin D Pearlman, MD, PhD, FACC PENDING

[would you include in agent selection TIMOSYN^® (Tee’ ko sin) (dofetilide) 

http://www.fda.gov/downloads/Drugs/DrugSafety/UCM266314.pdf

http://www.cardiocarelive.com/tikosyn-isi/index.cfm?User.Username=larry.bernstein@gmail.com&Contact.FirstName=Larry%20&Contact.LastName=Bernstein&Contact.Email=larry.bernstein@gmail.com&Location.Address1=%5B35%5D&Location.Address2=%5B40%5D&Location.City=%5B50%5D&Location.State=%5B55%5D&Location.Country=%5B60%5D&Location.Zip=%5B45%5D&Custom.Degree=%5B115%5D&Location.ShortDescription=%5B1%5D

http://labeling.pfizer.com/ShowLabeling.aspx?id=639  ]

START NOT A PRIORITY – till CVD 1,2,3 is done

2.2.2 Topics for CVD4 where We will work on

“Heart Failure and Regenerative Medicine: Multimodal Cardiovascular Imaging Technologies”

2.2.2.1    Heart Failure from 2.2 and

2.2.2.2 Content derived from all the innovations in:

Lev-Ari, A. & Abourjaily, P. (2006a) “An Investigation of the Potential of circulating Endothelial Progenitor Cells (cEPC) as a Therapeutic Target for Pharmacologic Therapy Design for Cardiovascular Risk Reduction.”

Part I: Macrovascular Disease – Therapeutic Potential of cEPCs – Reduction methods for CV risk.

Part II: (2006b) Therapeutic Strategy for cEPCs Endogenous Augmentation: A Concept-based Treatment Protocol for a Combined Three Drug Regimen.

Part III: (2006c) Biomarker for Therapeutic Targets of Cardiovascular Risk Reduction by cEPCs Endogenous Augmentation using New Combination Drug Therapy of Three Drug Classes and Several Drug Indications. Northeastern University, Boston, MA 02115

2.2.2.3 Multimodal Cardiovascular Imaging Technologies

END NOT A PRIORITY – till CVD is done

______________________________